EP3212290A4 - SERPIN FUSION POLYPEPTIDES AND METHODS OF USE - Google Patents
SERPIN FUSION POLYPEPTIDES AND METHODS OF USE Download PDFInfo
- Publication number
- EP3212290A4 EP3212290A4 EP15854670.5A EP15854670A EP3212290A4 EP 3212290 A4 EP3212290 A4 EP 3212290A4 EP 15854670 A EP15854670 A EP 15854670A EP 3212290 A4 EP3212290 A4 EP 3212290A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- fusion polypeptides
- serpin fusion
- serpin
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008847 Serpin Human genes 0.000 title 1
- 108050000761 Serpin Proteins 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000003001 serine protease inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3212290A1 EP3212290A1 (en) | 2017-09-06 |
EP3212290A4 true EP3212290A4 (en) | 2019-01-23 |
Family
ID=55858243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15854670.5A Pending EP3212290A4 (en) | 2014-10-27 | 2015-10-27 | SERPIN FUSION POLYPEPTIDES AND METHODS OF USE |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP3212290A4 (es) |
JP (2) | JP6737781B2 (es) |
KR (2) | KR20240005109A (es) |
CN (2) | CN114316068A (es) |
AU (3) | AU2015339507B2 (es) |
BR (1) | BR112017008525A2 (es) |
CA (1) | CA2965151A1 (es) |
HK (1) | HK1244460A1 (es) |
IL (2) | IL308589A (es) |
MX (2) | MX2017005467A (es) |
RU (1) | RU2746550C2 (es) |
SG (2) | SG10201903142RA (es) |
UA (1) | UA127305C2 (es) |
WO (1) | WO2016069574A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3873926A1 (en) * | 2018-10-29 | 2021-09-08 | Spin Therapeutics, LLC | Compositions and methods for alpha-1-antitrypsin disorders |
WO2020097946A1 (zh) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
US20240067703A1 (en) * | 2020-12-21 | 2024-02-29 | Macquarie University | Treatment of glaucoma |
GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
CA3205815A1 (en) * | 2021-03-03 | 2022-09-09 | Alwin REITER | Formulations of ace2 fc fusion proteins |
CN113325181A (zh) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用 |
CN114874333A (zh) * | 2021-10-18 | 2022-08-09 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
US20230364208A1 (en) | 2022-05-16 | 2023-11-16 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092219A2 (en) * | 2003-04-10 | 2004-10-28 | Protein Design Labs, Inc | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2013003641A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
US20130058919A1 (en) * | 2002-03-01 | 2013-03-07 | Xencor, Inc. | Optimized Fc Variants and Methods for their Generation |
WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000052160A1 (en) * | 1999-03-01 | 2000-09-08 | Human Genome Sciences, Inc. | Human serpin proteins |
PE20050251A1 (es) * | 2003-07-18 | 2005-04-13 | Vertex Pharma | Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc |
EP3192872A1 (en) * | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
JP4652414B2 (ja) * | 2004-11-12 | 2011-03-16 | ゼンコー・インコーポレイテッド | FcRnとの変化した結合を有するFc変異体 |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2083081A1 (en) * | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
MX2008002101A (es) * | 2005-08-12 | 2008-04-19 | Schering Corp | Fusiones de la proteina-1 quimiotactica de monocito. |
AU2009262199B2 (en) * | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
AU2009335798B2 (en) * | 2008-12-19 | 2014-11-27 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
AU2011349719B2 (en) * | 2010-12-23 | 2016-09-15 | Janssen Biotech, Inc. | Active protease-resistant antibody Fc mutants |
CN103476795B (zh) * | 2011-03-29 | 2016-07-06 | 罗切格利卡特公司 | 抗体Fc变体 |
WO2013003649A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Wap domain fusion polypeptides and methods of use thereof |
EP2802653A4 (en) * | 2012-01-10 | 2015-09-02 | Univ Colorado Regents | ALPHA-1 ANTITRYPSIN FUSION MOLECULE COMPOSITIONS, METHODS AND USES THEREOF |
AR091476A1 (es) * | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | POLIPEPTIDOS DE FUSION DE REGION Fc DE POLIPEPTIDO DE LIGANDO RECEPTOR DE INCRETINA Y CONJUGADOS CON FUNCION EFECTORA Fc ALTERADA |
ES2602030T3 (es) * | 2012-08-02 | 2017-02-17 | F. Hoffmann-La Roche Ag | Método para producir RFc solubles como fusión de Fc con la región Fc de inmunoglobulina inerte y usos de los mismos |
KR20180049238A (ko) * | 2012-12-05 | 2018-05-10 | 솔라 바이오사이언시즈 엘엘씨 | 단백질 발현 증진 폴리펩타이드 |
-
2015
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/zh active Pending
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/ko active Application Filing
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/pt active Search and Examination
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/ko not_active IP Right Cessation
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 UA UAA201705128A patent/UA127305C2/uk unknown
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/zh active Pending
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/ru active
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/ja active Active
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/es unknown
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/es unknown
-
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/zh unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/ja active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
-
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130058919A1 (en) * | 2002-03-01 | 2013-03-07 | Xencor, Inc. | Optimized Fc Variants and Methods for their Generation |
WO2004092219A2 (en) * | 2003-04-10 | 2004-10-28 | Protein Design Labs, Inc | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2013003641A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
WO2014001325A1 (en) * | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of WO2016069574A1 * |
Also Published As
Publication number | Publication date |
---|---|
IL251799B1 (en) | 2023-12-01 |
AU2015339507B2 (en) | 2021-07-01 |
WO2016069574A1 (en) | 2016-05-06 |
KR20240005109A (ko) | 2024-01-11 |
HK1244460A1 (zh) | 2018-08-10 |
CA2965151A1 (en) | 2016-05-06 |
MX2017005467A (es) | 2017-11-30 |
JP6737781B2 (ja) | 2020-08-12 |
MX2021012047A (es) | 2021-11-03 |
JP2020180157A (ja) | 2020-11-05 |
RU2017118325A (ru) | 2018-11-29 |
RU2746550C2 (ru) | 2021-04-15 |
AU2015339507A1 (en) | 2017-05-11 |
BR112017008525A2 (pt) | 2018-01-30 |
IL251799A0 (en) | 2017-06-29 |
RU2017118325A3 (es) | 2019-03-21 |
AU2024203586A1 (en) | 2024-06-20 |
AU2021240153A1 (en) | 2021-10-28 |
CN107206257A (zh) | 2017-09-26 |
SG11201703390SA (en) | 2017-05-30 |
UA127305C2 (uk) | 2023-07-19 |
JP2017537888A (ja) | 2017-12-21 |
IL308589A (en) | 2024-01-01 |
EP3212290A1 (en) | 2017-09-06 |
IL251799B2 (en) | 2024-04-01 |
CN114316068A (zh) | 2022-04-12 |
KR20170091096A (ko) | 2017-08-08 |
SG10201903142RA (en) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275307B (en) | Syntac polypeptides and their uses | |
HRP20190028T1 (hr) | Interleukin-2 fuzijski proteini i njihove primjene | |
EP3390624A4 (en) | MODIFIED POLYPEPTIDES AND METHOD OF USE THEREOF | |
EP3148573A4 (en) | Ox40l fusion proteins and uses thereof | |
EP3147298A4 (en) | Pd-l1 fusion protein and use thereof | |
EP3154582A4 (en) | Anti-tnf-alpha glycoantibodies and uses thereof | |
EP3455263A4 (en) | CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | |
HK1244460A1 (zh) | 絲氨酸融合多肽和其使用方法 | |
EP3154972A4 (en) | Azamophinan derivatives and use thereof | |
EP3349851A4 (en) | LIGHT-RESPONSIBLE POLYPEPTIDES AND METHOD OF USE THEREOF | |
EP3240576A4 (en) | Methods of transdifferentiation and methods of use thereof | |
HK1243443A1 (zh) | C1酯酶抑制劑融合蛋白及其用途 | |
EP3107569A4 (en) | Anti-acth antibodies and use thereof | |
EP3129094A4 (en) | Bougie and method of making and using same | |
EP3199543A4 (en) | Novel peptide and use thereof | |
EP3092248A4 (en) | Fusion polypeptides and methods of use | |
EP3407871A4 (en) | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | |
EP3193755A4 (en) | Fusion systems and methods of assembly and use | |
GB201410031D0 (en) | Polypeptides and uses thereof | |
EP3237452A4 (en) | Fusion proteins and methods thereof | |
EP3322736A4 (en) | FUSION POLYPEPTIDES AND METHOD OF USE | |
EP3325499A4 (en) | Novel peptide and use thereof | |
EP3209697A4 (en) | Fn14-binding proteins and uses thereof | |
EP3204003A4 (en) | Selenosugars and therapeutic uses thereof | |
EP3166406A4 (en) | Cytokine-chitosan bioconjugates and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170511 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244460 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/24 20060101ALI20180808BHEP Ipc: C07K 14/81 20060101ALI20180808BHEP Ipc: C07K 16/00 20060101ALI20180808BHEP Ipc: A61P 37/00 20060101AFI20180808BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190104 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/00 20060101AFI20181220BHEP Ipc: C07K 16/24 20060101ALI20181220BHEP Ipc: C07K 16/00 20060101ALI20181220BHEP Ipc: C07K 14/81 20060101ALI20181220BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20211104 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230523 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INHIBRX, INC. |